The pathogenesis of cancer related fatigue: Could increased activity of pro-inflammatory cytokines be the common denominator?

European Journal of Cancer

Volumn 44, Issue 2, 2008, Pages 175-181

  Jager, A ^a   Sleijfer, S ^a   van der Rijt, C C D ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anaemia; Cancer related fatigue; CRF; Hypothalamic pituitary adrenal axis; Pathogenesis; Pro inflammatory cytokines; Serotonin

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; DOCETAXEL; ETOPOSIDE; GAMMA INTERFERON; GRANISETRON; HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 8; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ONDANSETRON; PACLITAXEL; PAROXETINE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ANEMIA; ARTHRALGIA; ARTICLE; BRAIN METABOLISM; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; ERYTHROCYTE TRANSFUSION; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; MONOTHERAPY; NEOPLASM; NEUTROPENIA; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; SEROTONIN METABOLISM; TRYPTOPHAN BRAIN LEVEL;

ANEMIA; CLINICAL TRIALS AS TOPIC; CYTOKINES; FATIGUE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEOPLASMS; PITUITARY-ADRENAL SYSTEM; SEROTONIN; SYNAPSES;

EID: 38349075032     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.11.023     Document Type: Article

References (44)

1. Stone P., Richardson A., Ream E., Smith A.G., Kerr D.J., and Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 11 (2000) 971-975
2. Jean-Pierre P., Figueroa-Moseley C.D., Kohli S., Fiscella K., Palesh O.G., and Morrow G.R. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12 Suppl. 1 (2007) 11-21
3. Hofman M., Ryan J.L., Figueroa-Moseley C.D., Jean-Pierre P., and Morrow G.R. Cancer-related fatigue: the scale of the problem. Oncologist 12 Suppl. 1 (2007) 4-10
4. Curt G.A., Breitbart W., Cella D., Groopman J.E., Horning S.J., Itri L.M., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5 (2000) 353-360
5. Carroll J.K., Kohli S., Mustian K.M., Roscoe J.A., and Morrow G.R. Pharmacologic treatment of cancer-related fatigue. Oncologist 12 Suppl. 1 (2007) 43-51
6. Ahlberg K., Ekman T., Gaston-Johansson F., and Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 362 (2003) 640-650
7. Mustian K.M., Morrow G.R., Carroll J.K., Figueroa-Moseley C.D., Jean-Pierre P., and Williams G.C. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 12 Suppl. 1 (2007) 52-67
8. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
9. Schubert C., Hong S., Natarajan L., Mills P.J., and Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21 (2007) 413-427
10. Malik U.R., Makower D.F., and Wadler S. Interferon-mediated fatigue. Cancer 92 (2001) 1664-1668
11. Hieber U., and Heim M.E. Tumor necrosis factor for the treatment of malignancies. Oncology 51 2 (1994) 142-153
12. Sosman J.A., Aronson F.R., Sznol M., et al. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin Cancer Res 3 1 (1997) 39-46
13. Nishimoto N., Kanakura Y., Aozasa K., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106 (2005) 2627-2632
14. Wood L.J., Nail L.M., Perrin N.A., Elsea C.R., Fischer A., and Druker B.J. The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs 8 (2006) 157-169
15. Pusztai L., Mendoza T.R., Reuben J.M., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25 (2004) 94-102
16. Monk J.P., Phillips G., Waite R., et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 24 (2006) 1852-1859
17. Ludwig H., Van Belle S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004) 2293-2306
18. Birgegard G., Aapro M.S., Bokemeyer C., et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68 Suppl. 1 (2005) 3-11
19. Fallowfield L., Gagnon D., Zagari M., et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 87 12 (2002) 1341-1353
20. Echteld M.A., Passchier J., Teunissen S., Claessen S., de Wit R., and van der Rijt C.C. Multidimensional fatigue and its correlates in hospitalised advanced cancer patients. Eur J Cancer 43 6 (2007) 1030-1036
21. Blohmer J.U., Dunst J., Harrison L., et al. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 68 S1 (2005) 12-21
22. Vaupel P., Kelleher D.K., and Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28 (2001) 29-35
23. Bohlius J., Wilson J., Seidenfeld J., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3 (2006) CD003407
24. Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Clinical Oncology/American Society of Hematology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. J Clin Oncol, 2007; 25: in press. [Epub ahead of print].
25. Wichers M., and Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 5 (2002) 375-388
26. Shanks N., Harbuz M.S., Jessop D.S., Perks P., Moore P.M., and Lightman S.L. Inflammatory disease as chronic stress. Ann NY Acad Sci 840 (1998) 599-607
27. Bower J.E., Ganz P.A., and Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 67 (2005) 277-280
28. Lundstrom S., and Furst C.J. Symptoms in advanced cancer: relationship to endogenous cortisol levels. Palliat Med 17 (2003) 503-508
29. Bruera E., Ernst S., Hagen N., et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 2 (1998) 74-78
30. Bruera E., Roca E., Cedaro L., Carraro S., and Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69 (1985) 751-754
31. Soares D.D., Coimbra C.C., and Marubayashi U. Tryptophan-induced central fatigue in exercising rats is related to serotonin content in preoptic area. Neurosci Lett 415 (2007) 274-278
32. Bailey S.P., Davis J.M., and Ahlborn E.N. Serotonergic agonists and antagonists affect endurance performance in the rat. Int J Sports Med 14 (1993) 330-333
33. Fernstrom J.D., and Fernstrom M.H. Exercise, serum free tryptophan, and central fatigue. J Nutr 136 (2006) 553S-559S
34. Wilson W.M., and Maughan R.J. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 77 (1992) 921-924
35. Jones E.A. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 354 (1999) 397
36. Piche T., Vanbiervliet G., Cherikh F., et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut 54 (2005) 1169-1173
37. Theal J.J., Toosi M.N., Girlan L., et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 41 (2005) 1305-1312
38. Muller N., and Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12 (2007) 988-1000
39. Zhu C.B., Blakely R.D., and Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31 (2006) 2121-2131
40. Schmitz K.H., Holtzman J., Courneya K.S., Masse L.C., Duval S., and Kane R. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 14 (2005) 1588-1595
41. Milak M.S., Parsey R.V., Keilp J., Oquendo M.A., Malone K.M., and Mann J.J. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry 62 (2005) 397-408
42. Morrow G.R., Hickok J.T., Roscoe J.A., et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 21 (2003) 4635-4641
43. Roscoe J.A., Morrow G.R., Hickok J.T., et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89 (2005) 243-249
44. Prue G., Rankin J., Allen J., Gracey J., and Cramp F. Cancer-related fatigue: a critical appraisal. Eur J Cancer 42 (2006) 846-863